KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eli Lilly (LLY) Cash from Operations (2016 - 2025)

Historic Cash from Operations for Eli Lilly (LLY) over the last 17 years, with Q4 2025 value amounting to $3.2 billion.

  • Eli Lilly's Cash from Operations rose 3034.48% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $16.8 billion, marking a year-over-year increase of 9066.68%. This contributed to the annual value of $16.8 billion for FY2025, which is 9066.68% up from last year.
  • As of Q4 2025, Eli Lilly's Cash from Operations stood at $3.2 billion, which was up 3034.48% from $8.8 billion recorded in Q3 2025.
  • Eli Lilly's Cash from Operations' 5-year high stood at $8.8 billion during Q3 2025, with a 5-year trough of -$312.0 million in Q4 2023.
  • In the last 5 years, Eli Lilly's Cash from Operations had a median value of $1.8 billion in 2021 and averaged $2.2 billion.
  • Its Cash from Operations has fluctuated over the past 5 years, first tumbled by 11876.47% in 2023, then skyrocketed by 89291.67% in 2024.
  • Over the past 5 years, Eli Lilly's Cash from Operations (Quarter) stood at $2.3 billion in 2021, then decreased by 26.48% to $1.7 billion in 2022, then crashed by 118.76% to -$312.0 million in 2023, then soared by 892.92% to $2.5 billion in 2024, then soared by 30.34% to $3.2 billion in 2025.
  • Its Cash from Operations was $3.2 billion in Q4 2025, compared to $8.8 billion in Q3 2025 and $3.1 billion in Q2 2025.